IGF1R and hepatocellular carcinoma: The findings of this study demonstrate a potential correlation between IGF1R and YAP in the development of sorafenib resistance and suggest that the combination of the YAP-specific inhibitor verteporfin and sorafenib may be an effective treatment for HCC.